Answers are grounded in this paper and cite their sources.
This review discusses the efficacy and biological mechanisms by which somatotropin (ST) and β-adrenergic agonists improve growth performance. These metabolism modifiers increase growth rate, improve productive efficiency (feed efficiency), and increase carcass leanness. The ST-dependent reduction in adipose tissue accretion is the result of remarkable decreases in glucose transport, lipogenesis, and the ability of insulin to stimulate these processes in the adipocyte. Lipolysis is not affected by pST. The effects of ST are chronic in nature rather than acute, as was previously believed. This temporal profile may reflect a ST-dependent decrease in the transcription of important regulatory genes such as the glucose transporter(s) and key lipogenic enzymes. The effects of ST on cell proliferation are mediated by insulin-like growth factor I (IGF-I). A number of IGF binding proteins (IGFBP) are found in serum and are produced locally in a wide variety of tissues. The IGFBP have been shown to modulate the biological effects of IGF-I. The effects observed (either stimulatory or inhibitory) depend on the IGFBP used and the tissue studied. The significance of IGFBP-dependent modulation of IGF-I action remains to be established. β-adrenergic agonists (clenbuterol, cimaterol, and ractopamine) also alter growth rate and carcass composition of growing meat animals. β-adrenergic agonists seem to decrease carcass fat content by decreasing lipogenesis and stimulating lipolysis. The increase in muscle growth observed in animals treated with β-adrenergic agonists is associated with an enhancement of satellite cell proliferation, stimulation of myofibrillar protein synthesis, and depression of myofibrillar protein degradation.
No takes yet. Share an insight, caveat, or question.
Etherton et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: